Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (480)	12/28/1999 12:54:00 AM
From: Vector1	Read Replies (1) \| Respond to of 52153

Peter, I fear some of the biotechs are becoming substantially overvalued. I can see the arguments with companies like MLMN, AFFX and INCY, but INVG and CALP getting close to a billion in valuation is a little ridiculous. INVG is a nice little tools company that should probably trade at 35-40x earnings. CALP has some interesting technology but we are a long way from a lab on chip making real market penetration. Why do you think SEPR has not yet caught fire. V1